Optimal surgery for advanced gastric cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 12, 2009, Pages 1849-1858

  Songun, Ilfet ^a   Van De Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced gastric cancer; Locoregional control; Lymph node dissection; Morbidity; Mortality; Surgery; Survival

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; EPIRUBICIN;

ADJUVANT THERAPY; ADVANCED CANCER; ANASTOMOSIS LEAKAGE; CANCER CLASSIFICATION; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GASTRECTOMY; HUMAN; LAPAROTOMY; LYMPHADENECTOMY; MORBIDITY; OVERALL SURVIVAL; PANCREAS RESECTION; PARTIAL GASTRECTOMY; POSTOPERATIVE COMPLICATION; PROGNOSIS; RECURRENCE RISK; REOPERATION; REVIEW; SPLENECTOMY; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH SURGERY; SURGICAL APPROACH; SURGICAL RISK; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TOTAL STOMACH RESECTION; TREATMENT FAILURE;

GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; POSTOPERATIVE COMPLICATIONS; SPLENECTOMY; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 73349112556     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.132     Document Type: Review

References (71)

1. Macintyre IM, Akoh JA. Improving survival in gastric cancer: review of operative mortality in English language publications from 1970. Br. J. Surg. 78, 771-776 (1991).
2. Akoh JA, Macintyre IM. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br. J. Surg. 79(4), 293-299 (1992).
3. Wanebo H, Kennedy BJ, Chmiel J, Steele G, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann. Surg. 218, 583-592 (1993).
4. Kinoshita T, Maruyama K, Sasako M et al. Treatment results of gastric cancer patients: Japanese experience. In: Gastric Cancer. Nishi M, Ichakawa H, Nakajima T et al (Eds). Springer-Verlag, Tokyo, Japan 319-330 (1993).
5. Soga J, Kobayashi K, Saito J, Fujimaki M, Muto T. The role of lymphadenectomy in curative surgery for gastric cancer. World J. Surg. 3(6), 701-708 (1979).
6. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N. Engl. J. Med. 340, 908-914 (1999).
7. Bonenkamp JJ, van de Velde CJ, Kampschoer GH et al. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World J. Surg. 17(3), 410-414 (1993).
8. Cuschieri A. Recent advances in gastrointestinal malignancy. Ann. Chir. Gynaecol. 78(3), 228-237 (1989).
9. Siewert JR, Bottcher K, Roder JD et al. Prognostic relevance of systemic lymph node dissection in gastric carcinoma. Br. J. Surg. 80, 1015-1018 (1993).
10. Sue-Ling HM, Johnston D, Martin IG et al. Gastric cancer: a curable disease in Britain [see comments]. BMJ 307(6904), 591-596 (1993).
11. Arak A, Kull K. Factors influencing survival of patients after radical surgery for gastric cancer. A regional study of 406 patients over a 10-year period. Acta Oncol. 33(8), 913-920 (1994).
12. Wanebo HJ, Kennedy BJ, Winchester DP et al. Gastric carcinoma: does lymph node dissection alter survival? J. Am. Coll. Surg. 183, 616 (1996).
13. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br. J. Surg. 75, 110-112 (1988).
14. Robertson CS, Chung SC, Woods SD et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann. Surg. 220, 176-182 (1994).
15. Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J. Clin. Oncol. 22(11), 2069-2077 (2004). •• Results after 11 years of follow-up showing that some patients benefit from D2 dissection.
16. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Cooperative group. Br. J. Cancer 79(9-10), 1522-1530 (1999).
17. McCulloch P, Nita ME, Kazi H, Gama-Rodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst. Rev. CD001964 (2004).
18. Degiuli M, Sasako M, Calgaro M et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur. J. Surg. Oncol. 30(3), 303-308 (2004).
19. Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 7, 309-315 (2006).
20. Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer. An interim safety analysis of a multicenter, randomized, clinical trial. Am. J. Surg. 193(1), 10-15 (2007).
21. Yonemura Y, Wu C-C, Fukushima N et al. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int. J. Clin. Oncol. 13, 132-137 (2008).
22. Sasako M, Sano T, Yamamoto S et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N. Engl. J. Med. 359(5), 453-462 (2008). •• Extended lymphadenectomy beyond D2 does not improve survival.
23. Viste A, Ha'ugstvedt T, Eide GE, Sreide O. Postoperative complications and mortality after surgery for gastric cancer. Ann. Surg. 207, 7-13 (1988).
24. Bottcher K, Siewert JR, Roder JD, Busch R, Hermanek P, Meyer HJ. Risk of surgical therapy of stomach cancer in Germany. Results of the German 1992 Stomach Cancer Study. German Stomach Cancer Study Group ('92). Chirurg 65(4), 298-306 (1994).
25. Gennari L, Bozzetti F, Bonfanti G et al. Subtotal versus total gastrectomy for cancer of the lower two- thirds of the stomach: a new approach to an old problem. Br. J. Surg. 73, 534-538 (1986).
26. Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity amd mortality after D1 and D2 resection for gastric cancer: preliminary results of the MRC randomized controlled surgical trial. Lancet 347, 995-999 (1996).
27. Sasako M. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br. J. Surg. 84(11), 1567-1571 (1997).
28. Songun I, Bonenkamp JJ, Hermans J, van Krieken JH, van de Velde CJ. Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer. Eur. J. Cancer 32A(3), 433-437 (1996).
29. Kim SH, Karpeh MS, Klimstra DS, Leung D, Brennan MF. Effect of microscopic resection line disease on gastric cancer survival. J. Gastrointest. Surg. 3, 24-33 (1999).
30. Bozzetti F, Marubini E, Bonfanti G et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann. Surg. 230, 170-178 (1999).
31. Kim JH, Park SS, Kim J et al. Surgical outcomes for gastric cancer in the upper third of the stomach. World J. Surg. 30, 1870-1876 (2006).
32. Kodera Y, Yamamura Y, Shimizu Y et al. Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma. World J. Surg. 21(6), 622-627 (1997).
33. Kitamura K, Nishida S, Ichikawa D et al. No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. Br. J. Surg. 86(1), 119-122 (1999).
34. Wu CW, Chang IS, Lo SS et al. Complications following D3 gastrectomy. post hoc analysis of a randomized trial. World J. Surg. 30(1), 12-16 (2006).
35. Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A, Kurita A. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br. J. Surg. 92(9), 1103-1109 (2005).
36. Csendes A, Burdiles P, Rojas J et al. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 131, 401-407 (2002). • Higher septic complication rate after splenectomy without better survival.
37. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br. J. Surg. 93, 559-563 (2006). • Splenectomy had no impact on survival in patients with metastatic lymph nodes at the hilum of the spleen or along the splenic artery.
38. Wang JY, Huang TJ, Chen FM et al. A comparative study of pancreatectomy and pancreas-preserving gastrectomy in advanced gastric carcinomas. Hepatogastroenterology 51, 1229-1232 (2004). • Morbidity was significantly higher after distal pancreatectomy.
39. Kunisaki C, Shimada H, Nomura M et al. Clinical impact of metastatic lymph node ratio in advanced gastric cancer. Anticancer Res. 25(2B), 1369-1375 (2005).
40. Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large USpopulation database. J. Clin. Oncol. 23, 7114-7124 (2005).
41. Marchet A, Mocellin S, Ambrosi A et al. The prognostic value of N-ratio in patients with gastric cancer: validation in a large multicenter trial. Eur. J. Surg. Oncol. 34(2), 159-165 (2008).
42. Kampschoer GH, Maruyama K, van de Velde CJH, Sasako M, Kinoshita T, Okabayashi K. Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. Br. J. Surg. 76, 905-908 (1989).
43. Peeters KC, Hundahl SA, Kranenbarg EK et al. Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. World J. Surg. 29, 1576-1584 (2005).
44. Hundahl SA, Peeters KC, Kranenbarg EK et al. Improved regional control and survival with 'low Maruyama Index' surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial. Gastric Cancer 10, 84-86 (2007). •• 'Low Maruyama Index' surgery enhances regional control and survival.
45. Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann. Surg. Oncol. 9, 278-286 (2002).
46. Siewert JR, Kelsen D, Maruyama K et al. Gastric Cancer Diagnosis and Treatment - An Interactive Training Program (1st Edition). Springer Electronic Media, Heidelberg, Germany (2000).
47. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J. Clin. Oncol. 21(19), 3647-3650 (2003).
48. Peeters KC, Kattan MW, Hartgrink HH et al. Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer 103(4), 702-707 (2005).
49. Novotny AR, Schuhmacher C, Busch R et al. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann. Surg. 243(1), 74-81 (2006).
50. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann. Intern. Med. 137, 511-520 (2002).
51. Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann. Surg. 245, 777-783 (2007).
52. Damhuis RA, Meurs CJ, Dijkhuis CM, Stassen LP, Wiggers T. Hospital volume and post-operative mortality after resection for gastric cancer. Eur. J. Surg. Oncol. 28, 401-405 (2002).
53. Thompson AM, Rapson T, Gilbert FJ, Park KG. Hospital volume does not influence long-term survival of patients undergoing surgery for oesophageal or gastric cancer. Br. J. Surg. 94, 578-584 (2007).
54. Wenner J, Zilling T, Bladstrom A, Alvegard TA. The influence of surgical volume on hospital mortality and 5-year survival for carcinoma of the oesophagus and gastric cardia. Anticancer Res. 25, 419-424 (2005).
55. Xirasagar S, Lien YC, Lin HC, Lee HC, Liu TC, Tsai J. Procedure volume of gastric cancer resections versus 5-year survival. Eur. J. Surg. Oncol. 34, 23-29 (2008).
56. Meyer HJ. The influence of case load and the extent of resection on the quality of treatment outcome in gastric cancer. Eur. J. Surg. Oncol. 31, 595-604 (2005).
57. Bachmann MO, Alderson D, Edwards D et al. Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. Br. J. Surg. 89, 914-922 (2002).
58. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N. Engl. J. Med. 349, 2117-2127 (2003). •• Demonstrates that for many procedures, the observed associations between hospital volume and operative mortality are largely mediated by surgeon volume.
59. Bilimoria KY, Bentrem DJ, Feinglass JM et al. Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. J. Clin. Oncol. 26, 4626-4633 (2008). •• Based on 243,103 patients from the National Cancer Database, when comparing low- with high-volume hospitals, the hazard ratios for perioperative mortality were substantially larger than for long-term survival. A larger number of deaths could be avoided by focusing quality initiatives on factors associated with long-term survival.
60. McCulloch P, Niita ME, Kazi H, Gama-Rodrigues JJ. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br. J. Surg. 92(1), 5-13 (2005).
61. McCulloch P. D1 versus D2 dissection for gastric cancer (letter). Lancet 158, 413-418 (1995).
62. Parikh D, Johnson M, Chagla L, Lowe D, McCulloch P. D2 gastrectomy: lessons from a prospective audit of the learning curve. Br. J. Surg. 83(11), 1595-1599 (1996).
63. Krijnen P, den Dulk M, Meershoek-Klein Kranenbarg E, Jansen-Landheer ML, van de Velde CJ. Improved survival after resectable non-cardia gastric cancer in The Netherlands: the importance of surgical training and quality control. Eur. J. Surg. Oncol. 35 (7), 715-720 (2009).
64. Maruyama K, Gunven P, Okabayashi K, Sasako M, Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann. Surg. 210, 596-602 (1989).
65. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int. J. Radiat. Oncol. Biol. Phys. 8, 1-11 (1992).
66. Allum WH, Hallissey MT, Ward LC, Hockey MS. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br. J. Cancer 60, 739-744 (1989).
67. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355(1), 11-20 (2006). •• In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of epirubicin, cisplatin and 5-fluorouracil decreased tumor size and stage and significantly improved progression-free and overall survival.
68. MacDonald J, Smalley S, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345, 725-730 (2001). •• Outcome of this study resulted in chemoradiotherapy after gastrectomy becoming standard of care in the United States.
69. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357(18), 1810-1820 (2007).
70. Song J, Oh SJ, Kang WH, Hyung WJ, Choi SH, Noh SH. Robot-assisted gastrectomy with lymph node dissection for gastric cancer: lessons learned from an initial 100 consecutive procedures. Ann. Surg. 249(6), 927-932 (2009).
71. Japanese Research Society of Gastric Cancer. Japanese Classification of Gastric Carcinoma. First English Edition. Kanehara and Co., Ltd, Tokyo, Japan (1995).